Pooled antibiotic susceptibility testing that evaluates how antibiotics perform against the infection as a whole — including in polymicrobial cases. Results in 24–36 hours.
Identifies genetic abnormalities in patients with Barrett’s esophagus and surfaces indication of progression that may require additional procedures or targeted management.
Cytology, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) on brushings — distinguishing patient chromosomal alterations with high sensitivity and specificity for level of dysplasia and adenocarcinoma.
For at-risk esophageal adenocarcinoma patients, or patients who already have a Barrett’s esophagus diagnosis and need risk-stratification.
Distinguishes low-grade from high-grade dysplasia to inform management.
Brushing specimen in a ThinPrep PreservCyt vial (used for both FISH and IHC). Transport at room temperature in the brushing transport kit.
One brushing supports cytology, IHC, and the four-probe FISH panel.
Detects gains and losses of MYC (8q24), p16 (CDKN2A at 9p21), HER2 (ERBB2 at 17q12), and ZNF217 (20q13) — all associated with higher-risk disease.
Confirms histology when results are concordant; flags for further investigation when they differ.
Each marker has a known association with dysplastic changes in Barrett’s esophagus — combined to support patient-specific decisions.
Concentration and activity recently identified as a useful biomarker for dysplasia in ulcerative colitis, Crohn’s disease, and Barrett’s esophagus.
IHC of p53 expression is of interest in Barrett’s patients with a diagnosis of indefinite for dysplasia or low-grade dysplasia.
IHC staining for MIB-1, the Ki-67 proliferation antigen — the staining pattern appears gradually with disease progression.
Stains the acidic mucin present in goblet cells — supports the cytological assessment of intestinal metaplasia.
Quantifies chromosomal material / DNA with sufficient resolution to detect the gain or loss of a single large chromosome.
Imparts a characteristic range of coloration to exfoliative cells, allowing critical examination of nuclei and cytoplasmic components.
At-risk esophageal adenocarcinoma patients, or patients who already have a Barrett’s esophagus diagnosis and need risk-stratification by level of dysplasia.
An esophageal brushing specimen, collected into a ThinPrep PreservCyt vial. The same specimen is used for both FISH and IHC. Transport at room temperature in the brushing transport kit.
The Barrett’s FISH panel uses a four-probe set targeting:
When FISH results are concordant with histology, they confirm the diagnosis. When they differ, the discrepancy suggests further investigation. Positive FISH results combined with concordant morphology support aggressive treatment decisions.
See additional clinical resources and peer-reviewed publications from Pathnostics.
View Clinical Resources →Connect with a representative to learn how the panel can support stratification and management decisions for your patients.